Skip to main content

Keros Therapeutics, Inc.

KROS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001664710

In the last 90 days, Keros Therapeutics, Inc. insiders filed 2 open-market purchases and 4 sales; 132 institutions reported holding it in 13F filings for Q2 2026, worth $198.6M in total; no superinvestor holds it.

Q2 2021 vs. Q1 2021

How the institutions holding Keros Therapeutics, Inc. changed between Q1 2021 and Q2 2021.

All holders in Q2 2021All holders in Q1 2021

13F holders of KROS: Q1 2021 compared with Q2 2021
MeasureQ1 2021Q2 2021Change
Holders8380−3
Shares14.4M14.1M−291.7K (−2.0%)
Value$887.0M$599.7M−$287.3M (−32.4%)

New holders (13)

Institutions that held Keros Therapeutics, Inc. at the end of Q2 2021 but not at the end of Q1 2021.

Institutions new to KROS in Q2 2021
InstitutionSharesValue% of portfolio
Candriam Luxembourg S.C.A.101,409$4.31M0.03%
Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet LTD95,644$4.06M0.30%
Psagot Investment House Ltd.56,970$2.42M0.09%
Jasper Ridge Partners, L.P.45,473$1.93M0.10%
Alps Advisors Inc30,687$1.30M0.01%
American Financial Group Inc10,105$429.0K0.11%
Chescapmanager LLC10,105$429.0K0.07%
Susquehanna International Group, LLP8,723$370.0K0.00%
Ironsides Asset Advisors, LLC6,456$274.0K0.08%
Virtu Financial LLC5,144$218.0K0.02%
Soros Capital Management LLC4,705$200.0K0.03%
Ayalon Holdings Ltd.1,694$70.0K0.02%
Signaturefd, LLC18$1.00K0.00%

Sold out (16)

Institutions that held Keros Therapeutics, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.